Trial Profile
Randomized study of AZD9291 treatment of EGFR M+ NSCLC patients progressing on first line erlotinib. A study based upon detection of EGFR M+ ctDNA in plasma and urine.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Oct 2020
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms RAPID
- 29 Oct 2020 Status changed from recruiting to completed.
- 02 Jul 2018 New trial record